Sai Life Sciences joins the global ‘COVID Moonshot’ project
Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other viruses.
Sai Life Sciences, today announced its collaboration with the COVID Moonshot
project that aims to deliver an antiviral drug candidate effective
against COVID-19. With an in-kind contribution of a team of Medicinal
Chemists and supporting infrastructure, Sai Life Sciences will help
synthesize and profile analogues for NCEs and other previously known
compounds tested for other viruses.
PostEra, a biotechnology company specialising in machine learning for
drug discovery, is leading the initiative. Joining them are leading
experts in the fields of computational drug discovery, chemical
synthesis and biochemical assays. In the three months since its start in
February this year, the team has already identified over 60
experimentally-confirmed ‘fragments’ that effectively target a key
protein associated with COVID-19. It has now opened a crowdsourcing
initiative to accelerate the design of potential drug candidates from
these fragments and received over 4000 submissions from contributors
around the world.
Welcoming Sai Life Sciences into the consortium, CEO of PostEra Aaron
Morris, said, "We are immensely grateful for Sai Life Sciences’
contribution to this project. They are helping take the most promising
crowdsourced ideas from the Moonshot platform and turning these ideas
into chemical reality. It is generosity like this that gives us hope
that this moonshot of a project could achieve something ground-breaking
in our search for an effective COVID antiviral.”
Speaking about its participation in the project, CEO & Managing
Director of Sai Life Sciences, Krishna Kanumuri said, “We are delighted
to join this important global initiative. The consortium approach to
finding treatments for patients in the fight against COVID-19 is a
worthy cause and something that aligns very well with our purpose of
working with partners to accelerate solutions for improving life.”
Over the past two decades, Sai Life Sciences has built up a portfolio
of NCE Discovery services on the foundation of a strong chemical
synthesis platform. The company today offers innovator biotechs and
pharmaceutical companies the full spectrum of Discovery services from
Target ID & Validation through till IND, in addition to a robust
suite of capabilities across NCE development and cGMP manufacturing.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance